{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T01:30:41Z","timestamp":1773538241819,"version":"3.50.1"},"reference-count":75,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibodies"],"abstract":"<jats:p>This study aimed to investigate PD-L1 and PD-1 expression in circulating CD20+ cells in diffuse larger B-cell lymphoma (DLBCL) and to evaluate the predictive and diagnostic performance of PD-L1 versus PD-1 expression in circulating CD20+ cells in DLBCL. Percentages of CD20+, PD-L1+CD20+, and PD-1+CD20+ cells were measured by flow cytometry in 40 DLBCL blood samples and 19 healthy controls. The DLBCL patient group was subdivided into 20 newly diagnosed patients with no treatment yet and 20 patients that had finished six cycles of CHOP therapy. Percentages of PD-L1+CD20+ and PD-1+CD20+ cells were highly significantly increased in pre-therapy patients in comparison to healthy volunteers (p &lt; 0.001). Meanwhile, a significant decrease in percentages of PD-L1+CD20+ and PD-1+CD20+ was observed in post-CHOP therapy patients in comparison to pre-therapy patients (p &lt; 0.001). PD-L1+CD20+ cells were significantly decreased in post-therapy patients when compared to normal controls (p &lt; 0.001), while not for PD-1+CD20+ cells. A strong significant positive correlation between percentages of PD-L1+CD20+ and PD-1+CD20+ was detected in DLBCL patients (p &lt; 0.001). In the pre-therapy group, high PD-L1+CD20+ and PD-1+CD20+ percentages were correlated with serum LDH levels (p = 0.021, p &lt; 0.001). High percentages of PD-1+CD20+ were found in DLBCL patients with splenomegaly (p = 0.027). The results revealed that patients with advanced tumor stages, poor ECOG performance, and non-GCB DLBCL type had increased percentages of PD-L1+CD20+ and PD-1+CD20+ cells. Moreover, PD-L1+CD20+ % and PD-1+CD20+ % were significantly increased in DLBCL patients with bone marrow involvement or B symptoms. The superiority of PD-L1+CD20+ over PD-1+CD20+ was more profound in DLBCL prediction [AUC: 1.0] and in discriminating newly diagnosed patients [AUC: 1.0]. The findings suggest that increased PD-L1\/PD-1 expression in peripheral CD20 cells may serve as a companion diagnostic marker for DLBCL. Moreover, percentages of PD-L1+CD20+ cells have better diagnostic performance with higher sensitivity and specificity than PD-1+CD20+ %.<\/jats:p>","DOI":"10.3390\/antib11010015","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T20:26:41Z","timestamp":1645043201000},"page":"15","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Diagnostic Performance of PD-L1 versus PD-1 Expression in Circulating CD20 Cells in Diffuse Large B-Cell Lymphoma"],"prefix":"10.3390","volume":"11","author":[{"given":"Manal Mohamed","family":"Saber","sequence":"first","affiliation":[{"name":"Clinical Pathology Department, Faculty of Medicine, Minia University, Minia 61519, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,16]]},"reference":[{"key":"ref_1","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer. Revised, 4th ed."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","article-title":"Non-Hodgkin lymphoma","volume":"390","author":"Armitage","year":"2017","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.18632\/oncotarget.27785","article-title":"Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine","volume":"11","author":"Lodhi","year":"2020","journal-title":"Oncotarget"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.clml.2014.05.002","article-title":"Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: A meta-analysis of gene expression profiling and immunohistochemistry algorithms","volume":"14","author":"Read","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I","article-title":"Hydroxy daunomycin (Adriamycin) combination chemotherapy in malignant lymphoma","volume":"38","author":"McKelvey","year":"1976","journal-title":"Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomized study of the MabThera International Trial (MInT) Group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","article-title":"Relapsed\/refractory diffuse large B-cell lymphoma","volume":"2011","author":"Friedberg","year":"2011","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_10","unstructured":"Hochberg, M.C., Silman, A.J., and Smolen, J.S. (2015). B-cell depletion. Rheumatology, ScienceDirect. [6th ed.]."},{"key":"ref_11","unstructured":"Ratcliffe, M.J.H. (2016). Classical complement pathway. Encyclopedia of Immunobiology, Oxford Academic Press."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1073\/pnas.82.6.1766","article-title":"Role of the Bp35 cell surface polypeptide in human B-cell activation","volume":"82","author":"Clark","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.4049\/jimmunol.135.6.3795","article-title":"The CD20 (Bp35) antigen is involved in the activation of B cells from the G0 to the G1 phase of the cell cycle","volume":"135","author":"Golay","year":"1985","journal-title":"J. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1309\/438N-E0FH-A5PR-XCAC","article-title":"Higher Levels of Surface CD20 Expression on Circulating Lymphocytes Compared with Bone Marrow and Lymph Nodes in B-Cell Chronic Lymphocytic Leukemia","volume":"116","author":"Huh","year":"2001","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1172\/JCI61245","article-title":"Hodgkin lymphoma","volume":"122","author":"Engert","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/08820130500496878","article-title":"A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry","volume":"35","author":"Olejniczak","year":"2006","journal-title":"Immunol. Investig."},{"key":"ref_17","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2008). Diffuse large B-cell lymphoma, not otherwise specified. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, WHO."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1586\/17474086.2015.1007862","article-title":"CD20-negative diffuse large B-cell lymphomas: Biology and emerging therapeutic options","volume":"8","author":"Castillo","year":"2015","journal-title":"Expert Rev. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3109\/10428194.2011.608447","article-title":"Large B-cell lymphomas with plasmablastic differentiation: A biological and therapeutic challenge","volume":"53","author":"Montalban","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1309\/AJCPV1I2QWKZKNJH","article-title":"Plasmablastic lymphoma and related disorders","volume":"136","author":"His","year":"2011","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1200\/JCO.2008.21.5020","article-title":"Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: A rare clinicopathologic entity with poor prognosis","volume":"27","author":"Laurent","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d\u2019 Etude des Lymphomes de l\u2019 Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"International Trial Group: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MinT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL): Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomized controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_26","first-page":"1278","article-title":"CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin\u2019s disease: Associations with presenting features and clinical outcome","volume":"20","author":"Rassidakis","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_27","first-page":"811","article-title":"Rituximab therapy for follicular lymphoma: A comprehensive review of its efficacy as primary treatment, treatment for relapsed disease, retreatment, and maintenance","volume":"88","author":"Cohen","year":"2003","journal-title":"Haematologica"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/ncponc0638","article-title":"Rituximab and CHOP-like chemotherapy in good-prognosis diffuse large-B-cell lymphoma","volume":"3","author":"Coiffier","year":"2006","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"ref_30","first-page":"1","article-title":"Diagnosis and treatment of CD20 negative B cell lymphomas","volume":"16","author":"Atchi","year":"2017","journal-title":"Biomark Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/PPO.0000000000000061","article-title":"Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation","volume":"20","author":"Sanmamed","year":"2004","journal-title":"Cancer J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00262-004-0593-x","article-title":"Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: Implications for tumor immunotherapy","volume":"54","author":"Blank","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/ni1443","article-title":"The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection","volume":"8","author":"Sharpe","year":"2007","journal-title":"Nat. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"13110","DOI":"10.1038\/srep13110","article-title":"Development of PD-1\/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer","volume":"5","author":"He","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0165-2478(02)00142-6","article-title":"Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues","volume":"84","author":"Ishida","year":"2002","journal-title":"Immunol. Lett."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1158\/1078-0432.CCR-10-2660","article-title":"Programmed death-ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells","volume":"17","author":"Andorsky","year":"2011","journal-title":"Clin. Cancer. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma","volume":"126","author":"Kiyasu","year":"2015","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s40880-017-0262-z","article-title":"Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: A retrospective study","volume":"36","author":"Hu","year":"2017","journal-title":"Chin. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e6398","DOI":"10.1097\/MD.0000000000006398","article-title":"The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma","volume":"96","author":"Fang","year":"2017","journal-title":"Medicine"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1182\/blood.V126.23.3899.3899","article-title":"PD-L1 and PD1 expression in lymphomas","volume":"126","author":"Gatalica","year":"2015","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1182\/blood-2015-02-567453","article-title":"Immune checkpoint blockade in hematologic malignancies","volume":"125","author":"Armand","year":"2015","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrclinonc.2016.168","article-title":"PD-1\u2013PD-L1 immune-checkpoint blockade in B-cell lymphomas","volume":"14","author":"Goodman","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_44","unstructured":"(2019). Non-Hodgkin Lymphoma Treatment, American Cancer Society."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"ref_47","first-page":"e335","article-title":"Simple prognostic model for patients with advanced cancer based on performance status","volume":"10","author":"Jang","year":"2014","journal-title":"J. Politics"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1148\/radiol.2015142088","article-title":"Imaging for staging and response assessment in lymphoma","volume":"276","author":"Johnson","year":"2015","journal-title":"Radiology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.4049\/jimmunol.170.3.1257","article-title":"Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production","volume":"170","author":"Ma","year":"2003","journal-title":"J. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Nakamoto, N., Cho, A., Shaked, A., Olthoff, K., Valiga, M.E., Kaminski, M., Gostick, E., Price, D.A., Freeman, G.J., and Wherry, E.J. (2009). Synergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1\/CTLA-4 Blockade. PLoS Pathog., 5.","DOI":"10.1371\/journal.ppat.1000313"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5819","DOI":"10.1128\/JVI.00024-07","article-title":"Elevated expression levels of inhibitory receptor programmed death 1 on simian immunodeficiency virus-specific CD8 T cells during chronic infection but not after vaccination","volume":"81","author":"Velu","year":"2007","journal-title":"J. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/eji.201444911","article-title":"CD25(+) Bcl6(low) T follicular helper cells provide help to maturing B cells in germinal centers of human tonsil","volume":"45","author":"Li","year":"2015","journal-title":"Eur. J. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1182\/blood.V99.9.3256","article-title":"Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure","volume":"99","author":"Polyak","year":"2002","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1203\/01.PDR.0000130480.51066.FB","article-title":"Biliary atresia is associated with CD4+ Th1 cell-mediated portal tract inflammation","volume":"56","author":"Mack","year":"2004","journal-title":"Pediatr. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e234","DOI":"10.1016\/S1470-2045(15)70103-8","article-title":"Programmed cell death-1 inhibition in lymphoma","volume":"16","author":"Hawkes","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/pcmr.12340","article-title":"PD-L1 expression in melanoma shows marked heterogeneity within and between patients: Implications for anti\u2014PD","volume":"28","author":"Madore","year":"2014","journal-title":"1\/PD-L1 clinical trials. Pigment. Cell Melanoma Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13045-017-0479-y","article-title":"Clinical applications of PD-L1 bioassays for cancer immunotherapy","volume":"10","author":"Liu","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40364-017-0093-8","article-title":"Utility of PD-L1 immunohistochemistry assays for predicting PD-1\/PD-L1 inhibitor response","volume":"5","author":"Diggs","year":"2017","journal-title":"Biomark Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.molimm.2019.02.009","article-title":"PD-1-expressing B cells suppress CD4+ and CD8+ T cells via PD-1\/PD-L1- dependent pathway","volume":"109","author":"Wang","year":"2019","journal-title":"Mol. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-15-1408","article-title":"PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression","volume":"6","author":"Xiao","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5997","DOI":"10.1038\/ncomms6997","article-title":"PDL1hi B cells are critical regulators of humoral immunity","volume":"6","author":"Khan","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamaoncol.2015.2151","article-title":"Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor\u2014Infiltrating lymphocytes, and expression of PD-1 and PD-L1","volume":"1","author":"Howitt","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_64","first-page":"1384","article-title":"Expression and significance of PDL-1, HSP90, and HSP90 \u03b1 in serum of patients with acute leukemia","volume":"25","author":"Ma","year":"2017","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomized controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1572-0241.2006.00948.x","article-title":"Expression of PD-1, PD-L1, and PD-L2 in the liver in autoimmune liver diseases","volume":"102","author":"Mataki","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.7150\/jca.47816","article-title":"Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients","volume":"11","author":"Fei","year":"2020","journal-title":"J. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1002\/cam4.874","article-title":"PD-1 expression on the surface of peripheral blood CD4(+) T cell and its association with the prognosis of patients with diffuse large B-cell lymphoma","volume":"5","author":"Zhang","year":"2016","journal-title":"Cancer Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"44960","DOI":"10.18632\/oncotarget.16680","article-title":"Mechanisms of PD-1\/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: A summary of immunohistochemical studies","volume":"8","author":"Gravelle","year":"2017","journal-title":"Oncotarget"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","article-title":"PD-1 expression and clinical PD-1 blockade in B-cell lymphomas","volume":"131","author":"Zhou","year":"2018","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1309\/AJCP3CP6VFZJYMTK","article-title":"Pathology consultation on intermediate-to-large B-cell lymphomas","volume":"141","author":"Montgomery","year":"2014","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e1026530","DOI":"10.1080\/2162402X.2015.1026530","article-title":"Several immune escape patterns in non-Hodgkin\u2019s lymphomas","volume":"4","author":"Laurent","year":"2015","journal-title":"Oncoimmunology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1182\/blood-2015-12-686550","article-title":"Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas","volume":"127","author":"Georgiou","year":"2016","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1182\/blood.V128.22.153.153","article-title":"PD-L1 expression identifies high risk diffuse large B-cell lymphoma and is associated with several genomic markers","volume":"128","author":"Siddiqi","year":"2016","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e1294299","DOI":"10.1080\/2162402X.2017.1294299","article-title":"PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy","volume":"6","author":"Kleinovink","year":"2017","journal-title":"Oncoimmunology"}],"container-title":["Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4468\/11\/1\/15\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:20:57Z","timestamp":1760134857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4468\/11\/1\/15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,16]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["antib11010015"],"URL":"https:\/\/doi.org\/10.3390\/antib11010015","relation":{},"ISSN":["2073-4468"],"issn-type":[{"value":"2073-4468","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,16]]}}}